Understanding the genetic background of LQTS allows for improved risk stratification and the implementation of genotype-specific management strategies to prevent sudden cardiac death.
Answers are grounded in this paper and cite their sources.
Supports genotype-guided LQTS management; leaves open need for prospective outcome validation before routine adoption.
This review discusses the risk of cardiac events and genotype-based management of LQTS. We describe here the genetic background of long QT syndrome and the eleven different genes for ion-channels and a structural anchoring protein associated with that disorder. Clinical Background section discusses the risk of cardiac events associated with different LQTS types. Management and Prevention section describes in turn gene-specific therapy, which was based on the identification of the gene defect and the dysfunction of the associated transmembrane ion channel. In patients affected by LQTS, genetic analysis is useful for risk stratification and for making therapeutic decisions. A recent study reported a quite novel pathogenic mechanism for LQTS and suggested that treatments aimed at scaffolding proteins rather than specific ion channels may be an alternative to antiarrhythmic strategy in the future.
No takes yet. Share an insight, caveat, or question.
Markiewicz‐Łoskot et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: